Compare TG Therapeutics Inc (TGTX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Tencent Music Entertainment Group - ADR trades at $7.9 (market cap $13.10B). The key difference: Tencent Music Entertainment Group - ADR is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 3.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TME | |
|---|---|---|
Market Cap | $8.36B | $13.10B |
Sector | Health | Media |
52-Week High | $59.06 | $26.36 |
52-Week Low | $26.94 | $7.89 |
Enterprise Value | $8.57B | $11.05B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with technical indicators signaling a bearish trend. The company reported strong Q2 2026 earnings with an EPS beat of $0.25 versus $0.24 expected, and revenue growth to $32.9B in 2025. However, recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
TME presents a value opportunity with a low P/E of 9.46 and a consensus price target of $12.15, but faces risks from slowing growth and intense competition. Investors should weigh solid fundamentals against near-term headwinds in the music streaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
